1. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1899–905. [PubMed] 2. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat. 2007;105(Suppl 1):7–17. [PMC free article] [PubMed] 3. Johnston SR. Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer—have they lost their way? Breast Cancer Res. 2005;7(3):119–30. [PMC free article] [PubMed] 4. Lonning PE. Aromatase inhibitors in breast cancer. Endocr Relat Cancer. 2004;11(2):179–89. [PubMed] 5. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009;30(4):343–75. [PubMed] 6. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol. 2000;25(1):1–16. [PubMed] 7. Bertelli G, Gangadhara S. Exemestane in postmenopausal women with early or advanced breast cancer: a review. Expert Opin Pharmacother. 2010;11(11):1933–42. [PubMed] 8. Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab. 1980;51(3):473–7. [PubMed] 9. Gale KE, Andersen JW, Tormey DC, et al. Hormonal treatment for meta-static breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994;73(2):354–61. [PubMed] 10. Harvey HA, Lipton A, White DS, et al. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res. 1982;42(8 Suppl):3451s–3. [PubMed] 11. Lipton A, Harvey HA, Santen RJ, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 1982;42(8 Suppl):3434s–6. [PubMed] 12. Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 1982;42(8 Suppl):3430s–3. [PubMed] 13. Brueggemeier RW. Aromatase inhibitors—mechanisms of steroidal inhibitors. Breast Cancer Res Treat. 1994;30(1):31–42. [PubMed] 14. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92(9):2247–58. [PubMed] 15. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19(10):2596–606. [PubMed] 16. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883–90. [PMC free article] [PubMed] 17. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18(7):1399–411. [PubMed] 18. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer. 2000;36(8):976–82. [PubMed] 19. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91. [PubMed] 20. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23(22):5138–47. [PubMed] 21. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559–70. [PubMed] 22. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53. [PubMed] 23. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71. [PubMed] 24. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455–62. [PubMed] 25. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007;25(19):2664–70. [PubMed] 26. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71. [PubMed] 27. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76. [PMC free article] [PubMed] 28. Lonning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22(3):503–14. [PMC free article] [PubMed] 29. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol. 2007;21(2):401–14. [PubMed] 30. Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 1992;52(21):5933–9. [PubMed] 31. Paridaens R, Thomas J, Wildiers J, et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs. 1998;9(8):675–83. [PubMed] 32. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res. 1997;3(7):1101–8. [PubMed] 33. Takagi K, Miki Y, Nagasaki S, et al. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer. 2010;17(2):415–30. [PubMed]
34. Pfizer Inc., NY; NY: Oct, 2008. Aromasin® exemestane tablets [prescribing information]
35. Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics. 2010;20(10):575–85. [PMC free article] [PubMed] 36. Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos. 2011;39(1):98–105. [PubMed] 37. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321–31. [PubMed]
38. Bliss JM, Kilburn LS, Coleman RE, et al. Disease related outcomes with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES) Cancer Res. 2009;69(24 Suppl) Abstract 12.
39. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–92. [PubMed]
40. Goss PE, Ingle JN, Chapman J-A, et al. Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. Presented at: 33rd Annual San Antonio Breast Cancer Syposium; December 8–12, 2010; San Antonio, TX. Abstract S1–1.
41. Jones S, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 2009;69(2 Suppl 1) Abstract 15.
42. Markopoulos C, Dafni U, Misitzis J, et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study. Breast Cancer Res. 2009;11(3):R35. [PMC free article] [PubMed]
43. Seynaeve C, Hille E, Hasenburg A, et al. The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study. Presented at: 33rd Annual San Antonio Breast Cancer Syposium; December 8–12, 2010; San Antonio, TX. Abstract S2–3.
44. van de Velde CJH, Hille ETM, Rea D, et al. Discontinuation during tamoxifen in the sequential arm of the TEAM trial of adjuvant endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer: the effect of IES results and subsequent therapy. Presented at: 33rd Annual San Antonio Breast Cancer Syposium; December 8–12, 2010; San Antonio, TX. Abstract P5–11–17.
45. Hershman DL, Cheung AM, Chapman JW, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density: two-year results of the NCIC CTG MA.27 bone companion study. J Clin Oncol. 2011;29(Suppl) Abstract 518.
46. Markopoulos C, Polychronis A, Dafni U, et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek sub-study. Ann Oncol. 2009;20(1):49–55. [PubMed] 47. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–802. [PubMed] 48. Jones SE, Cantrell J, Vukelja S, et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol. 2007;25(30):4765–71. [PubMed]
49. Amir E, Ocana A, Niraula S, Carlsson L, Seruga B. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8–12, 2010; San Antonio, TX. Abstract S2–7.
50. Ewer MS, Glück S. A woman’s heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115(9):1813–26. [PubMed] 51. Din OS, Dodwell D, Wakefield RJ, Coleman RE. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010;120(3):525–38. [PubMed] 52. Shapiro CL. Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol. 2005;23(22):4847–9. [PubMed] 53. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14(Suppl 1):S20–40. [PMC free article] [PubMed] 54. Blaha P, Exner R, Borgo AD, et al. Is endocrine therapy really pleasant? Considerations about the long-term use of antihormonal therapy and its benefit/side effect ratio. Breast Care (Basel) 2009;4(3):155–61. [PMC free article] [PubMed] 55. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8(2):119–27. [PubMed] 56. Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat. 2010;124(1):153–61. [PubMed]
57. Rea D, Hasenburg A, Seynaeve C, et al. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prosepctive, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res. 2009;69(24 Suppl 3) Abstract 11.
58. Hadji P, Asmar L, van Nes JG, et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol. 2011;137(6):1015–25. [PubMed] 59. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28(31):4674–82. [PMC free article] [PubMed] 60. Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Ann Oncol. 2010;21(3):498–505. [PMC free article] [PubMed] 61. Kieback DG, Harbeck N, Bauer W, et al. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. Gynecol Oncol. 2010;119(3):500–5. [PubMed] 62. Hozumi Y, Suemasu K, Takei H, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol. 2011;22(8):1777–82. [PubMed] 63. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294–300. [PubMed] 64. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007;14(Suppl 1):S11–9. [PMC free article] [PubMed]
65. Thorne C. Clinical management of arthralgia and bone health in women undergoing aromatase inhibitor therapy. Curr Opin Oncol. 2007;19(suppl 1):S19–28.
66. Younus J, Kligman L. Management of aromatase inhibitor-induced arthralgia. Curr Oncol. 2010;17(1):87–90. [PMC free article] [PubMed] 67. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008;34(3):275–82. [PubMed] 68. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19(8):1407–1416. [PubMed] 69. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–57. [PubMed] 70. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24(6):910–7. [PubMed] 71. Dixon JM, Renshaw L, Langridge C, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat. 2011;125(3):741–9. [PubMed] 72. Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M. Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol (R Coll Radiol) 2004;16(7):485–91. [PubMed] 73. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007;10(5):367–76. [PubMed] 74. Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany. Breast Care (Basel) 2009;4(6):389–96. [PMC free article] [PubMed] 75. Lundkvist J, Wilking N, Holmberg S, Jonsson L. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat. 2007;102(3):289–99. [PubMed] 76. Risebrough NA, Verma S, Trudeau M, Mittmann N. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer. 2007;110(3):499–508. [PubMed]
77. El Ouagari K, Karnon J, Kaura S. Comparison of cost of distant disease-free year gained of aromatase inhibitors letrzole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective. Breast Cancer Res Treat. 106(Suppl 1):S104. Abstract 2059.
78. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):iii–iv. ix–xi, 1–134. [PubMed] 79. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2. [PubMed] 80. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57. [PubMed] 81. Glück S, Gorouhi F. Clinical and economic benefits of aromatase inhibitor therapy in early breast cancer. Am J Health Sys Pharm. 2011;68 [published online ahead of print Sep 15]. [PubMed] 82. Lamerato L, Havs.tad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106(9):1875–82. [PubMed]
83. Wiederkehr D, Kaura S, Mody-Patel N, Ogbonnaya A, Stern L. Cost associated with distant, contralateral, and local-regional breast cancer recurrence in a vertically integrated health care system. J Clin Oncol. 2008 May;26(20 suppl) Abstract 1141.
84. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010;73(2):156–66. [PubMed] 85. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–20. [PubMed] 86. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431–9. [PubMed]
87. Dent SF, Hopkins S, Di Valentin T, Verreault J, Vandermeer L, Verma S. Adjuvant aromatase inhibitors in early breast cancer—toxicity and adherence. Important observations in clinical practice. Breast Cancer Res Treat. 2007;106(Suppl 1):S111. Abstract 2079.
88. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor—positive breast cancer. J Clin Oncol. 2004;22(16):3309–15. [PubMed]
89. Salgado BA, Zivian MT. Aromatase inhbitiors: side effects reported by 622 women. Breast Cancer Res Treat. 2006;100(Suppl 1):S168. Abstract 3131.
90. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62. [PubMed] 91. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832–9. [PubMed] 92. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–6. [PubMed] 93. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–29. [PMC free article] [PubMed] 94. Glück S. The prevention and management of distant metastases in women with breast cancer. Cancer Invest. 2007;25(1):6–13. [PubMed] 95. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112(2):260–7. [PubMed] 97. Nabholtz JM, Mouret-Reynier MA, Durando X, et al. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin Pharmacother. 2009;10(9):1435–47. [PubMed]
98. Bartlett JM, Bloom KJ, Goldstein NS, et al. Mammostrat® as an immunohistochemical multigene assay for prediction of early relapse risk in postmenopausal early breast cancer: preliminary data of the TEAM pathology substudy. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8–12, 2010; San Antonio, TX. Abstract P3–10–33.
99. Bartlett JM, Brookes CL, Robson T, et al. The TEAM trial pathology study identifies potential prognostic and predictive biomarker models for postmenopausal patients treated with enodcrine therapy. Cancer Res. 2009;69(24 Suppl 3) Abstract 75.
100. Bartlett JMS, Brookes CL, van de Velde CJH, et al. Final results of a prospectively planned biomarker analysis: HER1–3 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the TEAM pathology sub-study. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8–12, 2010; San Antonio, TX. Abstract S2–4.
101. Bartlett JMS, Stocken D, van de Velde CJH, et al. An integration of biological and pathological marker panels in the TEAM pathology substudy: the impact of different parameters on risk estimation of relapse at both 2.75 and 5 years. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8–12, 2010; San Antonio, TX. Abstract P3–10–04.
102. Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score—results from TransATAC. Cancer Res. 2009;69(24 Suppl 3) Abstract 75.
103. Desmedt C, Giobbie-Hurder A, Neven P, et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial. BMC Med Genomics. 2009;2:40. [PMC free article] [PubMed] 104. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34. [PubMed] 105. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res. 2005;11(13):4835–42. [PubMed] 106. Van Belle V, Van Calster B, Brouckaert O, et al. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol. 2010;28(27):4129–34. [PubMed] 107. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26(34):5569–75. [PMC free article] [PubMed]
108. Yardley D, Green N, Papish S, et al. Rheumatologic evaluation of adjuvant letrozole in postmenopausal breast cancer patients discontinuing anastrozole due to grade 2–3 arthralgia—myalgia. Cancer Res. 2009;69(24 Suppl) Abstract 805.
109. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127–34. [PubMed] 110. Glück S, Mamounas T. Improving outcomes in early-stage breast cancer. Oncology (Williston Park) 2010;24(11 Suppl 4):1–15. [PubMed] 111. Bickell NA, LePar F, Wang JJ, Leventhal H. Lost opportunities: physicians’ reasons and disparities in breast cancer treatment. J Clin Oncol. 2007;25(18):2516–21. [PubMed]